Alejandro Martínez-Pradeda is an expert in Pharmacy at Complexo Hospitalario Universitario A Coruña (Spain). Alejandro Martínez-Pradeda has authored 12 publications, the most recent in 2025. SLR score: 41 (community average: 125). How the SLR is computed.

LeadR Profile

Alejandro Martínez-Pradeda Complexo Hospitalario Universitario A Coruña Spain
41 ScienceLeadR Reputation 41
Network Map

Pharmacy

Subspecialties: Biochemistry - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2019 - 2025
Source: PubMed

Complexo Hospitalario Universitario A Coruña - Farmacéutico Interno Residente

2019 - 2025

Complexo Hospitalario Universitario A Coruña - Farmacéutico adjunto - área oncohematología

2023 - 2025

Centro Oncológico de Galicia

2024 - 2025

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 12

Citations

Citations: 354 1st author: 2 Last author: 0 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Optimal Thromboprophylaxis in Laparoscopic Bariatric Surgery in a Private Third-Level Center in Mexico City.
PMID 40704261 — enoxaparin, embolism, heparin, bariatric surgery, pulmonary embolism, venous thromboembolism
Cureus20250
The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report.
PMID 40703266 — radiotherapy, cells, lung, silymarin, silybin, brain, neoplasms, carcinoma, non-small-cell lung, adenocarcinoma of lung, immunotherapy, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, therapeutics
Front Med (Lausanne)20251
Application of instant assembly of collagen to bioprint cardiac tissues.
PMID 40520649 — cells, bioprinting, collagen, tissue engineering, tissues
APL Bioeng20250
Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes.
PMID 40413564 — comorbidity, hematology, safety, neoplasms, leukemia, lymphocytic, chronic, b-cell, leukemia, drug therapy, leukemia, lymphoid, drug-related side effects and adverse reactions, drug tapering, therapeutics
Ann Pharmacother20250
Macromolecular crowding-based biofabrication utilizing unmodified extracellular matrix bioinks.
PMID 40268621 — cells, intestines, bioprinting, biocompatible materials, solutions, crowding, tissues, gels, extracellular matrix
Acta Biomater20250

LeadR Networks

Main global connection map